Taken together, these findings suggest that following gemcitabine therapy, MEPs directly affect CD8 + T cells and NK cells probably via the secretion of CXCL16 and CCL5, thereby contributing to anti-tumor immunity. This evidence concerns the gene CD8A and neoplasm.